লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

pfizer europe ma eeig, belgium - idarubicīna hidrohlorīds - pulveris injekciju šķīduma pagatavošanai - 5 mg

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

pfizer europe ma eeig, belgium - idarubicīna hidrohlorīds - pulveris injekciju šķīduma pagatavošanai - 10 mg

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

pfizer italia s.r.l., italy - idarubicīna hidrohlorīds - pulveris injekciju šķīduma pagatavošanai - 10 mg

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

bio products laboratory limited, united kingdom - cilvēka viii koagulācijas faktors - pulveris injekciju šķīduma pagatavošanai - 25 sv/ml

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

takeda austria gmbh, austria - haemoderivatum deproteinatum asins teļu, - Šķīdums injekcijām - 80 mg/2 ml

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

takeda austria gmbh, austria - haemoderivatum deproteinatum asins teļu, - Šķīdums injekcijām - 200 mg/5 ml

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

teva b.v., netherlands - diklofenaka nātrija sāls - Ārstnieciskais plāksteris - 140 mg

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

teva pharma b.v., netherlands - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 16 mg/12,5 mg

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

glaxosmithkline trading services limited, ireland - lacidipīns - apvalkotā tablete - 6 mg